OPTHEA LIMITED ORDINARY (OPT) Short Interest
OPTHEA LIMITED ORDINARY (ASX:OPT) had 0.00% of shares reported as short positions as of 16 July 2026, representing 28,186 shares. OPTHEA LIMITED ORDINARY operates in the Pharmaceuticals, Biotechnology & Life Sciences industry. Source: ASIC short position report (T+4 delay).
Source: official ASIC short position report, T+4 delay. Methodology · Disclaimer — not financial advice.
Opthea
Opthea is a biopharmaceutical company focused on developing innovative biologics-based therapies for treating vision-threatening eye diseases. The company is pioneering the development of sozinibercept, a first-in-class VEGF-C/D 'trap' inhibitor, aimed at improving treatment outcomes for wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME).
Short position
Price & short interest
Toggle series, zoom, and compare · ASIC daily, T+4OPT intelligence dossier
Public-source evidence for this company, with industry drill-up links.
- Tax paid and taxable income records
- Government contracts and public money
- Emissions and trade exposure
- Political donations and lobbying links
Short interest history & FAQ
Company
AI-generated research profile of Opthea
About
website
address
More Pharmaceuticals, Biotechnology & Life Sciences Stocks
Other shorted stocks in this sector
Be the first to discuss OPT
Start a research thread or post the first pulse update